Figure 6

Flowchart describing the workflow and study design. (a) Schematic image illustrating the 13 organ systems for the cancer cell lines included in the study. (b) Data sources and cell line availability in the different analyses. External validation was performed using cancer cell lines derived from breast, glioblastoma, melanoma, and multiple myeloma cancer, as well as CCLE mutation data to confirm the mutation frequency of 19 genes. KM-plotter was used to explore the influence of 32 of the 33 dysregulated genes on survival in patient samples representing 21 cancer types (pan-cancer). TIMER2.0 was used to validate gene expression relationship between genes involved in bortezomib-sensitivity and immune cells in different cancer types and genes involved in bortezomib-sensitivity and outcome in myeloma patients using MMRF-COMMPASS study. (c) Flowchart depicting the study design for the drug sensitivity screen, cell cycle distribution analysis, and apoptosis analysis using Annexin V.